Customize your JAMA Network experience by selecting one or more topics from the list below.
In this issue of JAMA, Janiaud et al1 present a meta-analysis of randomized clinical trials (RCTs) of convalescent plasma for the treatment of patients with COVID-19. Based on an analysis of 1060 patients from 4 RCTs published in peer-reviewed journals and 10 722 patients from 6 RCTs (5 published as preprints and 1 as a press release), the authors found that treatment with convalescent plasma vs placebo or standard of care was not associated with a significant decrease in all-cause mortality (risk ratio, 0.93 [95% CI, 0.63-1.38] for the 4 peer-reviewed RCTs; risk ratio, 1.02 [95% CI, 0.92-1.12] for all 10 RCTs) or with benefit for other clinical outcomes, including length of hospital stay, mechanical ventilation use, and clinical improvement or deterioration.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Angus DC, Gordon AC, Bauchner H. Emerging Lessons From COVID-19 for the US Clinical Research Enterprise. JAMA. 2021;325(12):1159–1161. doi:10.1001/jama.2021.3284
Create a personal account or sign in to: